Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Status:
Completed
Trial end date:
2020-07-21
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, nonrandomized study to determine the PK profiles of belinostat
in patients with relapsed/refractory solid tumors or hematological malignancies who have
heterozygous and homozygous UGT1A1*28 genotypes and wild-type UGT1A1 gene. Enrolled patients
will be assigned to 1 of 3 cohorts (A, B, or C) based on their UGT1A1 genotype